Patients with the metabolic syndrome (MS) have an increased risk of developing cardiovascular disease (CVD) and diabetes. Treatment goals to reduce this risk include aggressive lipid lowering. However, despite aggressive management with statins, there remains a high residual risk in patients with MS. Clinical trials continue to provide evidence that more aggressive risk factor modification results in improved CVD outcomes, but implementation and achievement of the myriad of goals frequently requires multiple therapeutic approaches. The addition of combination therapy with statins is emerging as the optimal therapeutic approach to further lower the risk of CVD in patients with MS.
|Original language||English (US)|
|Journal||Archives of Medical Science|
|Issue number||4 SUPPL. A|
|State||Published - Dec 1 2007|
- Metabolic syndrome
- Risk factors
ASJC Scopus subject areas